Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression

Psychedelics have emerged as a promising class thought to rapidly improve mood symptoms, primarily through activation of serotonin 5-HT2A receptors, triggering downstream changes that may promote neuroplasticity.¹ These effects may contribute to rapid antidepressant responses that persist beyond the acute psychedelic experience, potentially allowing durable benefit after only a limited number of treatment sessions.

Importantly, the US Food and Drug Administration’s (FDA) approval of J&J’s Spravato, an esketamine nasal spray, in March 2019, established a role for rapid-acting, clinic-administered treatments in TRD while also highlighting the commercial challenges associated with this model.² Treatment must be administered by a trained specialist in a certified health care setting, with patients monitored for at least 2 hours and initially requiring repeated treatment sessions, creating potential barriers around cost and access.

The psychedelic class is attempting to improve this trade-off: delivering rapid and durable efficacy with infrequent dosing through use of established clinical infrastructure, without creating a treatment experience so burdensome that it limits adoption.

Clinical Data and Regulatory Landscape Are Shifting Sentiment

Following years of skepticism and caution surrounding use of psychedelics in depression, 2026 has been a pivotal year in shifting sentiment, driven by late-stage clinical development and regulatory advances. Compass Pathways' COMP360, a synthetic formulation of psilocybin, delivered 2 positive phase 3 results in TRD,³ strengthening the evidence base supporting psilocybin’s use and advancing the program toward regulatory review stage, with FDA approval expected in early 2027.⁴ Similarly, Definium Therapeutics' DT120, an oral disintegrating LSD tablet, has produced positive phase 3 data in MDD,⁵ demonstrating that the potential of psychedelic therapies may extend beyond highly treatment-resistant populations to broader depression populations.

Regulatory breakthroughs have moved in parallel. The April 2026 White House executive order aimed at accelerating psychedelic treatments for serious mental illness,⁶ together with finalized FDA guidance for psychedelic clinical development,⁷ has provided greater visibility around the pathway from clinical development to potential commercialization.

That distinction is becoming increasingly important as additional programs reach late-stage development. Shorter-duration therapies such as AtaiBeckley’s BPL-003 (intranasal formulation of 5-MeO-DMT), and GH Research’s GH001 (inhaled formulation of 5-MeO-DMT), could potentially reduce the time patients need to remain under supervision, through different routes of administration and dosing schedules. BLP-003 is entering phase 3 development in 2026, with GH-001 pivotal trials expected by year-end 2026.⁸ As a result, competitors that successfully address the remaining practical limitations associated with treatment delivery could gain meaningful ground, even if they are not first to market.

Increasing Commercial Interest and Investment Momentum

Following the executive order, the FDA will now have to prioritize review of qualifying psychedelic products with Breakthrough Therapy Designation through the Commissioner’s National Priority Voucher program and facilitate patient access under the federal Right to Try Act. By reducing some of the administrative barriers associated with the class, the executive order has driven increased interest from investors and big pharmaceutical companies. Combined with positive late-stage clinical data across multiple programs, the evolving regulatory environment has helped to derisk further investment in the class.

Specifically, Lilly’s recent agreement to acquire AtaiBeckley for up to $3.8 billion (July 2026),⁹ represents one of the clearest signals to date that large pharmaceutical companies increasingly see strategic value in the psychedelics space. If completed, the agreement will provide Lilly with the rights to BPL-003, which may support greater commercial scalability vs competing therapies through its ~2-hour administration regimen and no requirement for adjunctive psychotherapy.

As these developments improve access to funding for smaller companies and provide investors with clearer exit pathways, continued market growth is likely to intensify competition and make differentiation increasingly important. Companies will therefore need distinct strategies to build proprietary intellectual property and target well-defined patient populations. This will be particularly important in depression, where the high prevalence of comorbidities creates opportunities to differentiate therapies and drive adoption within specific patient subgroups.¹⁰

What’s Next for Psychedelics in Depression?

Importantly, several operational hurdles remain. Companies such as Compass Pathways and Definium Therapeutics aim to address some of Spravato’s limitations through 1- to 2-session treatment models lasting 6 to 8 hours; however, their assets remain Schedule I, and the associated altered state of consciousness may constrain broader adoption. Even with regulatory progress and shifting sentiment, these therapies are likely to require Risk Evaluation and Mitigation Strategy (REMS) programs, similar to Spravato, given their abuse potential and need for supervised administration. DEA rescheduling could also delay commercial availability following potential approval.

Practical challenges around capacity, cost, and reimbursement may further limit uptake. Lengthy monitored sessions consume significant staff and treatment-room capacity, while the economics of delivery remain uncertain. Although Category III procedural codes for psychedelic monitoring, introduced in January 2024,¹¹ enable hour-by-hour reporting, reimbursement rates under these codes have yet to be established.

These hurdles raise several important questions for the field: How durable must efficacy be to justify supervised psychedelic treatment? How short can the psychedelic experience become without compromising clinical benefit? Can administration expand beyond specialized treatment centers? And which models will ultimately prove economically attractive to physicians, patients and payers? Upcoming clinical and regulatory catalysts should begin to provide answers. Ultimately, the companies best positioned to succeed may not simply be those that first validate psychedelics, but those that most effectively address the clinical, operational and economic barriers to their adoption.

Mr Komarov is a junior business analyst at Lifescience Dynamics in London with consulting experience across neurology and neuropsychiatry, with particular depth in major depressive disorder. He holds an MSc in Biotechnology and Pharmaceutical Management from University College London, where he conducted research on venture capital theory in CNS-focused biotech start-ups.

Dr Sundarakrishnan is a business analyst at Lifescience Dynamics in Toronto, with experience conducting competitive intelligence analysis across oncology, hematology, immunology, and neuroscience. She earned her PhD from McGill University, where her research focused on modelling depression-related states in rodents.

Dr Fleming is a senior business analyst at Lifescience Dynamics in London. She earned a doctorate in cancer biology from the Institute of Cancer Research in London before transitioning to work in biopharma consulting. She has supported clients across several indications, including MDD, bringing expertise in competitive intelligence.

Miss Law is a consultant at Lifescience Dynamics in London with several years of experience in Biopharma consulting. She has developed expertise in immunology, neurology and women’s health through supporting various clients in competitive intelligence projects.

References

1. Avram M, Borgwardt S. Psychedelics for major depression—from controlled research settings into broader clinical use. Cell Rep Med. 2025;6(9):102361.

2. Janssen announces U.S. FDA approval of Spravato (esketamine) CIII nasal spray for adults with treatment-resistant Depression (TRD) who have cycled through multiple treatments without relief. News release. March 5, 2019. Accessed September 29, 2026. https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief

3. Compass Pathways successfully achieves primary endpoint in second phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression. News release. February 17, 2026. Accessed September 29, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

4. Compass Pathways announces second quarter and first half 2026 financial results and business highlights. News release. August 5, 2026. Accessed September 29, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights/default.aspx

5. Definium Therapeutics announces positive topline results from phase 3 Emerge study of DT120 Orally Disintegrating Tablet (ODT) in major depressive disorder. News release. June 22, 2026. Accessed September 29, 2026. https://ir.definiumtx.com/news-events/press-releases/detail/232/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder

6. Accelerating medical treatments for serious mental illness. The White House. April 18, 2026. Accessed September 29, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

7. Psychedelic drugs: considerations for clinical investigations. FDA. July 2026. Accessed September 29, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

8. GH Research reports second quarter 2026 financial results and provides business update. News release. August 6, 2026. Accessed September 29, 2026. https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-second-quarter-2026-financial-results-and

9. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. News release. July 16, 2026. Accessed September 29, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant

10. Qiu H, Wang L, Zeng X, et al. Comorbidity patterns in depression: a disease network analysis using regional hospital discharge records. J Affect Disord. 2022;296:418-427.

11. Ostrovsky A, Barnett BS. New billing codes offer opportunity to investigate psychedelic treatment. Psychedelic Med (New Rochelle). 2024;2(3):184-186.